DDA'S Fractional Staffing Model Keeps Programs Moving

In drug development, the difference between a program that advances on schedule and one that stalls rarely comes down to the science. More often, it comes down to whether the right expertise was available at the right moment. For emerging biotech and biopharma companies, that expertise is frequently absent precisely when it is needed most: at the inflection points where CMC strategy, regulatory documentation, and manufacturing execution demand senior-level leadership.

Drug Discovery Alliances was built to solve this problem. Over 25 years and more than $100 million in deals brokered, DDA has developed a platform that gives drug development organizations access to seasoned CMC consultants, fractional executives, and Drug Makers in Residence without the overhead of full-time hiring.

The Problem DDA Solves

Most early-stage drug companies are lean by design. That is an asset when it comes to capital efficiency, but a liability when a program reaches a stage that demands breadth across chemistry, formulation, analytical development, quality systems, and regulatory CMC strategy simultaneously. Recruiting a full-time VP of CMC or Head of Regulatory Affairs takes months. The program cannot wait.

DDA bridges that gap by embedding proven pharmaceutical professionals directly into client programs. These are not generalist advisors. They are CMC executives, project managers, and technical specialists with track records across API manufacturing, formulation development, regulatory submissions, and GMP compliance who take ownership of deliverables and are accountable for outcomes.

What DDA Brings to Your Program

DDA's fractional staffing model is built around three core offerings:

•       Fractional CXO and CMC Leadership: Experienced executives who provide strategic CMC direction, regulatory agency interaction, and program governance on a defined engagement basis, scaled to your program's current needs

•       Drug Makers in Residence: Hands-on technical experts embedded within client teams to execute process development, method development, manufacturing scale-up, and technology transfer alongside internal staff

•       CMC Project Management: Dedicated program managers who provide governance structure, CRO and CDO oversight, risk tracking, and milestone accountability across the full development lifecycle

These engagements are supported by DDA's global network of preferred manufacturing and analytical suppliers, giving clients a fully integrated platform from discovery through commercialization rather than a single point of expertise.

Built for the Way Drug Development Actually Works

Drug programs are not linear, and organizational needs shift substantially between development stages. DDA's model is designed to scale with those shifts. Engagement scope expands during high-intensity periods such as pre-IND preparation, GMP manufacturing readiness, or regulatory submission cycles, and contracts during steadier phases, without the organizational friction of hiring and workforce reduction cycles.

The result is a development organization that can access CXO-level pharmaceutical expertise precisely when and where it generates the most value, while deploying capital efficiently across the programs that matter.

Partner with DDA

Whether you are navigating your first IND submission, scaling into GMP manufacturing, or building the CMC infrastructure your program needs to reach clinical stage, DDA has the team and the network to get you there.

info@drugdiscoveryalliances.com  |  (+1) 919-602-2167